Retatrutide is not FDA-approved. It is an investigational drug currently in Phase 3 clinical trials. This article summarizes published research for educational purposes — it is not medical advice, and it is not an endorsement of using retatrutide outside of a clinical trial.
What is retatrutide?
Retatrutide (development code LY3437943) is an experimental injectable peptide developed by Eli Lilly. It belongs to a class of drugs called incretin receptor agonists — the same drug family as semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) — but it goes a step further than either of them.
Where semaglutide activates one hormone receptor and tirzepatide activates two, retatrutide is a triple agonist: a single molecule engineered to activate three separate receptors at once — GLP-1, GIP, and glucagon. It's a 26-amino-acid peptide attached to a fatty acid chain, a modification that extends its half-life to roughly six days and allows for once-weekly subcutaneous injection.
As of September 2026, retatrutide has not been approved by the FDA, EMA, MHRA, or any other regulator, and it cannot be legally prescribed outside of a clinical trial. Eli Lilly's Phase 3 program (called TRIUMPH) has reported several successful trials since December 2025, with a regulatory submission to the FDA expected around late 2026 or early 2027.
How it works: three receptors, one molecule
Each of the three receptors retatrutide activates plays a different role in metabolism:
GLP-1 receptor (GLP-1R): This is the same target as semaglutide. Activating it slows how fast the stomach empties, boosts insulin release after meals, and sends satiety signals to the brain — the combination that makes people feel full sooner and eat less.
GIP receptor (GIPR): GIP works alongside GLP-1 to stimulate insulin release, but only when blood glucose is already elevated — a built-in safeguard against dropping blood sugar too low. It also affects how fat cells store and release fat. Retatrutide was engineered to have its strongest effect here.
Glucagon receptor (GCGR): This is retatrutide's defining feature — the receptor that separates it from both semaglutide and tirzepatide. Glucagon receptor activation increases the body's resting energy expenditure and directly signals the liver to break down stored fat. It's counterintuitive, since glucagon normally raises blood sugar, but retatrutide is designed so the insulin-boosting effects of the other two receptors offset this, resulting in a net improvement in blood sugar control despite the added glucagon activity.
What it does across the body
Because these three receptors sit on tissues throughout the body, retatrutide's effects extend well beyond appetite. Here's what clinical trials have measured so far:
Brain and appetite
GLP-1 receptors in the hindbrain (the area postrema and nucleus tractus solitarius) and GIP receptors in the hypothalamus work together to reduce hunger signaling and increase satiety. Researchers believe GIP receptor activity may also help blunt the nausea that GLP-1 activation alone tends to cause — a possible reason retatrutide's side-effect profile hasn't been dramatically worse despite hitting three targets instead of one.
Digestive system
Slower gastric emptying is part of why the drug works — it keeps people feeling full longer — but it's also the source of the most common side effects: nausea, vomiting, diarrhea, and constipation, especially during dose increases.
Pancreas and blood sugar
Both GLP-1 and GIP stimulate insulin secretion in a glucose-dependent way, meaning insulin only ramps up when blood sugar is actually elevated. In a Phase 2 trial in people with type 2 diabetes, HbA1c improved by an average of 2.2 percentage points, with 82% of participants reaching an HbA1c of 6.5% or lower after 36 weeks.
Liver
This is where retatrutide's results have been especially striking. In a Phase 2a trial focused specifically on liver fat (published in Nature Medicine), participants on the 12 mg dose saw liver fat drop by an average of 82.4% at 24 weeks, and 86% of them reached a normal liver fat level. The glucagon receptor component is thought to be the main driver, since it directly signals the liver to mobilize stored fat. A dedicated Phase 3 trial for MASLD (metabolic dysfunction-associated steatotic liver disease, formerly called NAFLD) is underway, with results expected later in 2026.
Fat tissue and energy expenditure
The glucagon receptor component increases resting energy expenditure — the body burns more calories at rest — on top of the reduced calorie intake driven by appetite suppression. This dual mechanism (eating less and burning more) is what researchers point to when explaining why retatrutide has outperformed single- and dual-receptor drugs on weight loss in trials so far.
Heart and blood vessels
Across the TRIUMPH Phase 3 program, retatrutide has consistently improved cardiovascular risk markers: in the TRIUMPH-4 trial, the 12 mg dose lowered systolic blood pressure by 14.0 mmHg, alongside reductions in non-HDL cholesterol, triglycerides, and high-sensitivity C-reactive protein (a marker of inflammation linked to heart disease). One trade-off: heart rate tends to rise by roughly 5–10 beats per minute, most noticeable around 24 weeks of treatment, then often stabilizing. A dedicated cardiovascular outcomes trial (TRIUMPH-Outcomes) is running separately to determine whether these marker improvements translate into fewer heart attacks and strokes — that hasn't been established yet.
Kidneys
Early data is encouraging but preliminary: in post-hoc analyses, the 12 mg dose reduced urine albumin-to-creatinine ratio (a marker of kidney stress) by roughly 31–37%, and estimated kidney filtration rate (eGFR) improved slightly in the obesity cohort. This hasn't been the focus of a dedicated trial yet.
Muscle and bone
As with other drugs in this class, rapid weight loss brings a real risk of losing lean muscle mass along with fat. Trial data suggests the proportion of muscle lost is roughly comparable to what's seen with lifestyle-based weight loss, but it's a legitimate concern for anyone losing a large percentage of body weight quickly. Maintaining adequate protein intake and resistance training are the two most commonly recommended countermeasures — for any rapid-weight-loss intervention, not specific to retatrutide.
What the clinical trials have shown
Trial Population Key result
Phase 2 (NEJM, 2023) Obesity, no diabetes Up to 24.2% weight loss at 48 weeks (12 mg)
Phase 2a MASLD substudy (Nature Medicine, 2024) Obesity with elevated liver fat Up to 82.4% liver fat reduction at 24 weeks
TRIUMPH-4 (Dec 2025) Obesity/overweight + knee osteoarthritis 28.7% weight loss at 68 weeks; 75.8% reduction in knee pain scores
TRIUMPH-1 (May 2026) General obesity, 2,339 participants 28.3% weight loss at 80 weeks (12 mg) vs. 2.2% placebo
TRANSCEND-T2D-1 (Mar 2026) Type 2 diabetes 16.8% weight loss at 40 weeks
Weight loss and metabolic improvements scale with dose, and results vary by individual. As with any weight-loss drug in this class, weight regain after stopping treatment is expected based on the mechanism, though this hasn't been fully characterized for retatrutide specifically.
Safety profile
The side effects reported so far are broadly similar to other incretin-based drugs, with a few differences:
Most common: nausea (roughly 40–50% of participants), diarrhea, constipation, and vomiting — mostly during dose escalation, generally mild-to-moderate, and tending to improve over time.
Heart rate increase: a modest, dose-dependent rise, attributed to the glucagon receptor component.
Dysesthesia: an unusual skin sensation (described as tingling or a "pins and needles" feeling) reported at higher doses in Phase 3 trials — something not commonly seen with GLP-1-only drugs.
Lean mass loss: a general risk of rapid, large-magnitude weight loss, not unique to this drug.
Discontinuation due to side effects: 2.2% (4 mg), 4.5% (9 mg), and 5.1% (12 mg) of participants stopped treatment, compared with 0% on placebo, across the TRIUMPH-1 trial.
Because retatrutide is still investigational, the full long-term safety picture — including rare or long-term risks — is not yet established. Serious risks discussed for this drug class in general (pancreatitis, gallbladder problems) are being monitored but haven't been clearly quantified for retatrutide specifically.
Where things stand (September 2026)
Eli Lilly's TRIUMPH program has enrolled more than 5,800 participants across trials in obesity, type 2 diabetes, knee osteoarthritis, obstructive sleep apnea, cardiovascular disease, and liver disease. Several trials have now reported positive topline results, and Lilly has indicated it plans to submit a New Drug Application to the FDA once sufficient Phase 3 data is available — estimated for late 2026 or early 2027. Until an approval decision is made, retatrutide remains available only to people enrolled in clinical trials.
Sources
Jastreboff AM, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity." New England Journal of Medicine, 2023.
Sanyal AJ, et al. "Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial." Nature Medicine, 2024. nature.com/articles/s41591-024-03018-2
Coskun T, et al. "LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist." Cell Metabolism, 2022.
Eli Lilly and Company, investor press release on TRIUMPH-4 topline results, December 2025. investor.lilly.com
"Triple Agonism Based Therapies for Obesity." PMC, National Library of Medicine. ncbi.nlm.nih.gov/pmc/articles/PMC12304053
Wikipedia, "Retatrutide" (for TRIUMPH program trial status). en.wikipedia.org/wiki/Retatrutide
PharmExec, "Lilly's Retatrutide Displays Positive Topline Results in Successful Phase III Trial," 2026.
This article is for informational purposes only and is not medical advice. Retatrutide is investigational and not approved for any use outside of clinical trials. Speak with a licensed healthcare provider before making decisions about any treatment.